[1]
|
Firouzabadi, N., Ghasemiyeh, P., Moradishooli, F. and Mohammadi-Samani, S. (2023) Update on the Effectiveness of COVID-19 Vaccines on Different Variants of SARS-CoV-2. International Immunopharmacology, 117, Article ID: 109968. https://doi.org/10.1016/j.intimp.2023.109968
|
[2]
|
Dupoirieux, L. (2023) COVID-19 Preoperative Blood Tests: What Do They Tell Us about COVID-19 Vaccines? Medicine and Clinical Science, 5, 1-3. https://doi.org/10.33425/2690-5191.1074
|
[3]
|
Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer S.R., Khan, F., et al. (2021) Impact and Effectiveness of mRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data. The Lancet, 15, 1819-1829. https://doi.org/10.1016/S0140-6736(21)00947-8
|
[4]
|
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., et al. (2022) Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 27, 340-350. https://doi.org/10.1056/NEJMoa2115481
|
[5]
|
Nordstrom, P., Ballin, M. and Nordstrom, A. (2022) Risk of Infection, Hospitalisation, and Death up to 9 Months after a Second Dose of COVID-19 Vaccine: A Retrospective, Total Population Cohort Study in Sweden. The Lancet, 26, 814-823. https://doi.org/10.1016/S0140-6736(22)00089-7
|
[6]
|
Yamamoto, K. (2022) Adverse Effects of COVID-19 Vaccines and Measures to Prevent Them. Virology Journal, 5, Article No. 100. https://doi.org/10.1186/s12985-022-01831-0
|
[7]
|
Ssentongo, P., Ssentongo, A.E., Voleti, N., Groff, D., Sun, A., Ba, D.M., et al. (2022) SARS-CoV-2 Vaccine Effectiveness against Infection, Symptomatic and Severe COVID-19: A Systematic Review and Meta-Analysis. BioMed Central Infectious Diseases, 22, Article No. 439. https://doi.org/10.1186/s12879-022-07418-y
|
[8]
|
Addo, I.Y., Dadzie, F.A., Okeke, S.R., Boadi, C. and Boadu, E.F. (2022) Duration of Immunity Following Full Vaccination against SARS-CoV-2: A Systematic Review. Archives of Public Health, 80, Article No. 200. https://doi.org/10.1186/s13690-022-00935-x
|
[9]
|
Chivu-Economescu, M., Vremera, T., Ruta, S.M., Grancea, C., Leustean, M., Chiriac, D., et al. (2022) Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study. Biomedicines, 10, Article No. 1526. https://doi.org/10.3390/biomedicines10071526
|
[10]
|
Evans, J.P., Zeng, C., Carlin, C., Lozanski, G., Saif, L.J., Oltz, E.M., et al. (2022) Neutralizing Antibody Responses Elicited by SARS-CoV-2 mRNA Vaccination Wane over Time and Are Boosted by Breakthrough Infection. Science Translational Medicine, 14, eabn8057. https://doi.org/10.1126/scitranslmed.abn8057
|
[11]
|
Hosseinian, S., Powers, K., Vasudev, M., Palma, A.M., de Assis, R., Jain, A., et al. (2022) Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 13, Article ID: 817345. https://doi.org/10.3389/fimmu.2022.817345
|
[12]
|
Sughayer, M.A., Souan, L., Abu Alhowr, M.M., Al Rimawi, D., Siag, M., Albadr, S., et al. (2022) Comparison of the Effectiveness and Duration of anti-RBD SARS-CoV-2 IgG Antibody Response between Different Types of Vaccines: Implications for Vaccine Strategies. Vaccine, 3, 2841-2847. https://doi.org/10.1016/j.vaccine.2022.03.069
|
[13]
|
Tanir, F., Mete, B., Demirhindi, H., Kara, E., Nazlican, E., Daglioglu, G., et al. (2022) Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines, 10, 1177. https://doi.org/10.3390/vaccines10081177
|
[14]
|
Balkan, I.I., Dinc, H.O., Can, G., Karaali, R., Ozbey, D., Caglar, B., et al. (2023) Waning Immunity to Inactive SARS-CoV-2 Vaccine in Healthcare Workers: Booster Required. Irish Journal of Medical Science, 192, 19-25. https://doi.org/10.1007/s11845-022-02984-1
|
[15]
|
Bozic, L., Knezevic, D., Travar, M., Miljus, N., Petkovic, M., Acimovic, J., et al. (2023) The Comparison of SARS-CoV-2 Antibody Levels in Medical Personnel Induced by Different Types of Vaccines Compared to the Natural Infection. Central European Journal of Immunology, 48, 35-42. https://doi.org/10.5114/ceji.2023.125239
|
[16]
|
Delicado-Useros, V., Navarro-Rodenas, E., Sánchez-Onrubia, I.M., Ortega-Martínez, C., Alfaro-Espín, A., Pérez-Serra, J.D., et al. (2023) Evolution of Acquired Humoral Immunity after Full Vaccination against SARS-CoV-2. IgG Levels in Healthcare Workers at 6 and 9 Months. World Journal of Vaccines, 13, 13-32. https://doi.org/10.4236/wjv.2023.132002
|
[17]
|
Shrotri, M., Krutikov, M., Nacer-Laidi, H., Azmi, B., Palmer, T., Gidding, R., et al. (2022) Duration of Vaccine Effectiveness against SARS-CoV-2 Infection, Hospitalisation, and Death in Residents and Staff of Long-Term Care Facilities in England (VIVALDI): A Prospective Cohort Study. Lancet Healthy Longevity, 3, e470-e480. https://doi.org/10.1016/S2666-7568(22)00147-7
|
[18]
|
Nanishi, E., Levy, O. and Ozonoff, A. (2022) Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review. Human Vaccines & Immunotherapics, 18, Article ID: 2045857. https://doi.org/10.1080/21645515.2022.2045857
|
[19]
|
Mwimanzi, F., Lapointe, H.R., Cheung, P.K., Sang, Y., Yaseen, F., Umviligihozo, G., et al. (2022) Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Journal of Infectious Diseases, 226, 983-994. https://doi.org/10.1093/infdis/jiac199
|
[20]
|
Müller, L. andrée, M., Moskorz, W., Drexler, I., Hauka, S., Ptok, J., et al. (2022) Adjusted COVID-19 Booster Schedules Balance Age-Dependent Differences in Antibody Titers Benefitting Risk Populations. Frontiers in Aging, 3, Article ID: 1027885. https://doi.org/10.3389/fragi.2022.1027885
|
[21]
|
Allen, N., Brady, M., Carrion Martin A.I., Domegan, L., Walsh, C., Houlihan, E., et al. (2021) SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. Microbiology Spectrum, 9, e0039121. https://doi.org/10.1128/Spectrum.00391-21
|
[22]
|
Müller, L., Kannenberg, J., Biemann, R., Honemann, M., Ackermann, G. and Jassoy, C. (2022) Comparison of the Measured Values of Quantitative SARS-CoV-2 Spike Antibody Assays. Journal of Clinical Virology, 155, Article ID: 105269. https://doi.org/10.1016/j.jcv.2022.105269
|
[23]
|
Meschi, S., Matusali, G., Colavita, F., Lapa, D., Bordi, L., Puro, V., et al. (2021) Predicting the Protective Humoral Response to a SARS-CoV-2 mRNA Vaccine. Clinical Chemistry and Laboratory Medicine, 59, 2010-2018. https://doi.org/10.1515/cclm-2021-0700
|
[24]
|
Goldblatt, D., Fiore-Gartland, A., Johnson, M., Hunt, A., Bengt, C., Zavadska, D., et al. (2022) Towards a Population-Based Threshold of Protection for COVID-19 Vaccines. Vaccine, 40, 306-315. https://doi.org/10.1016/j.vaccine.2021.12.006
|
[25]
|
Halfon, P., Jordana, S., Blachier, S., Cartlamy, P., Kbaier, L., Psomas, C.K., et al. (2023) Anti-Spike Protein to Determine SARS-CoV-2 Antibody Levels: Is There a Specific Threshold Conferring Protection in Immunocompromised Patients? PLOS ONE, 18, e0281257. https://doi.org/10.1371/journal.pone.0281257
|
[26]
|
Meijide Míguez, H., Montes García, I., Ochando Gómez, M., García Merino, I.M., Cano, E.L. and De La Torre, A. (2023) Immunogenicity, Effectiveness and Safety of COVID-19 Vaccine in Older Adults Living in Nursing Homes: A Real-Life Study. Revista Espanola de Geriatría y Gerontología. 58, 125-133. https://doi.org/10.1016/j.regg.2023.02.009
|
[27]
|
Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A.K., Honarpisheh, H., et al. (2022) SARS-CoV-2-Antibody Response in Health Care Workers after Vaccination or Natural Infection in a Longitudinal Observational Study. Vaccine, 40, 206-212. https://doi.org/10.1016/j.vaccine.2021.11.081
|
[28]
|
McGee, C., Shi, M., House, J., Drude, A., Gonzalez, G., Martin, N., et al. (2022) Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination. Microbiology Spectrum, 26, e0202622. https://doi.org/10.1128/spectrum.02026-22
|
[29]
|
Sariol, C.A.A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina-Rodríguez, A., Cruz, L., et al. (2021) Function Is More Reliable than Quantity to Follow up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses, 30, Article No. 1972. https://doi.org/10.3390/v13101972
|
[30]
|
Shenai, M.B., Rahme, R. and Noorchashm, H. (2021) Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. Cureus, 13, e19102. https://doi.org/10.7759/cureus.19102
|
[31]
|
Diani, S., Leonardi, E., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., et al. (2022) SARS-CoV-2—The Role of Natural Immunity: A Narrative Review. Journal of Clinical Medicine, 11, Article No. 6272. https://doi.org/10.3390/jcm11216272
|
[32]
|
Decru, B., Van Elslande, J., Steels, S., Van Pottelbergh, G., Godderis, L., Van Holm, B., et al. (2022) IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months after BNT162b2 Vaccination than after SARS-CoV-2 Infection in Healthcare Workers. Frontiers in Immunology, 15, Article ID: 909910. https://doi.org/10.3389/fimmu.2022.1098285
|
[33]
|
Krammer, F. (2021) A Correlate of Protection for SARS-CoV-2 Vaccines Is Urgently Needed. Nature Medicine, 27, 1147-1148. https://doi.org/10.1038/s41591-021-01432-4
|
[34]
|
Perry, J., Osman, S., Wright, J., Richard-Greenblatt, M., Buchan, S.A., Sadarangani, M., et al. (2022) Does a Humoral Correlate of Protection Exist for SARS-CoV-2? A Systematic Review. PLOS ONE, 17, e0266852. https://doi.org/10.1371/journal.pone.0266852
|